Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer
by
Jens Cardinale 1,*,†, René Martin 2, Yvonne Remde 1, Martin Schäfer 1, Antje Hienzsch 2, Sandra Hübner 2, Anna-Maria Zerges 2, Heike Marx 1, Ronny Hesse 2, Klaus Weber 1, Rene Smits 2, Alexander Hoepping 2, Marco Müller 2, Oliver C. Neels 1,3 and Klaus Kopka 1,3
Jens Cardinale 1,*,†, René Martin 2, Yvonne Remde 1, Martin Schäfer 1, Antje Hienzsch 2, Sandra Hübner 2, Anna-Maria Zerges 2, Heike Marx 1, Ronny Hesse 2, Klaus Weber 1, Rene Smits 2, Alexander Hoepping 2, Marco Müller 2, Oliver C. Neels 1,3 and Klaus Kopka 1,3
1
German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
2
ABX Advanced Biochemical Compounds GmbH, Heinrich-Glaeser-Strasse 10-14, 01454 Radeberg, Germany
3
German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
†
Current address: Ludwig Boltzmann Institute Applied Diagnostics, General Hospital Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria.
Pharmaceuticals 2017, 10(4), 77; https://doi.org/10.3390/ph10040077
Received: 15 August 2017 / Revised: 14 September 2017 / Accepted: 16 September 2017 / Published: 27 September 2017
(This article belongs to the Special Issue Emerging Theranostic Tracers in the Context of Radiopharmaceutical Drug Development)
Radiolabeled tracers targeting the prostate-specific membrane antigen (PSMA) have become important radiopharmaceuticals for the PET-imaging of prostate cancer. In this connection, we recently developed the fluorine-18-labelled PSMA-ligand [18F]PSMA-1007 as the next generation radiofluorinated Glu-ureido PSMA inhibitor after [18F]DCFPyL and [18F]DCFBC. Since radiosynthesis so far has been suffering from rather poor yields, novel procedures for the automated radiosyntheses of [18F]PSMA-1007 have been developed. We herein report on both the two-step and the novel one-step procedures, which have been performed on different commonly-used radiosynthesisers. Using the novel one-step procedure, the [18F]PSMA-1007 was produced in good radiochemical yields ranging from 25 to 80% and synthesis times of less than 55 min. Furthermore, upscaling to product activities up to 50 GBq per batch was successfully conducted. All batches passed quality control according to European Pharmacopoeia standards. Therefore, we were able to disclose a new, simple and, at the same time, high yielding production pathway for the next generation PSMA radioligand [18F]PSMA-1007. Actually, it turned out that the radiosynthesis is as easily realised as the well-known [18F]FDG synthesis and, thus, transferable to all currently-available radiosynthesisers. Using the new procedures, the clinical daily routine can be sustainably supported in-house even in larger hospitals by a single production batch.
View Full-Text
Keywords:
[18F]PSMA-1007; fluorine-18; PSMA; automation; prostate cancer; PET
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Cardinale, J.; Martin, R.; Remde, Y.; Schäfer, M.; Hienzsch, A.; Hübner, S.; Zerges, A.-M.; Marx, H.; Hesse, R.; Weber, K.; Smits, R.; Hoepping, A.; Müller, M.; Neels, O.C.; Kopka, K. Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer. Pharmaceuticals 2017, 10, 77.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
